We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge’s lead ...

RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic ...

RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases ...

On Monday, Morgan Stanley (NYSE:MS) initiated coverage on BioAge Labs Inc (NASDAQ:BIOA), assigning the stock an Overweight rating and setting a price target of $40.00. The new rating reflects the ...

On Monday, Citi initiated coverage on BioAge Labs Inc (NASDAQ:BIOA) shares, giving the biotech company a Buy rating and setting a price target of $45.00. The firm highlighted BioAge's focus on ...

Goldman Sachs initiated coverage of BioAge Labs (BIOA) with a Not Rated. The firm models for peak azelaprag sales of $8.5B in 2036 via peak penetration of 15% into the incretin-treated market.

On Monday, BioAge Labs Inc (NASDAQ:BIOA) stock received a positive outlook from a major financial institution, as coverage was initiated with a Buy rating and a price target set at $42. The ...

Investing.com -- BioAge Labs, a clinical-stage biotech company developing therapies for metabolic diseases, has attracted attention from Wall Street investment banks, with three analysts ...